JNCCN 360 - NSCLC - Available Clinical Trials

Editor:

David S. Ettinger, MD, FACP, FCCP

Advertisement

Advertisement

Available Clinical Trials

A Phase III, Randomized, Placebo-Controlled Clinical Study of SBRT With or Without Pembrolizumab in Participants With Medically Inoperable NSCLC (KEYNOTE-867)

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

Cleveland Clinic Taussig Cancer Institute

Fox Chase Cancer Center

Fred and Pamela Buffett Cancer Center

Fred Hutchinson Cancer Research Center / Seattle Cancer Care Alliance

Huntsman Cancer Institute at the University of Utah

LATIFY: Ceralasertib Plus Durvalumab vs Docetaxel in NSCLC Whose Disease Progressed on or After Prior Anti–PD(L)1 Therapy and Platinum-Based Chemotherapy

Mayo Clinic Cancer Center

Memorial Sloan Kettering Cancer Center

Moffitt Cancer Center

Osimertinib With or Without Bevacizumab as Initial Treatment of EGFR-Mutant Lung Cancer

Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

The University of Texas MD Anderson Cancer Center

UC San Diego Moores Cancer Center

UCSF Helen Diller Family Comprehensive Cancer Center

University Hospitals Seidman Cancer Center

University of Colorado Cancer Center

University of Michigan Comprehensive Cancer Center

University of Wisconsin Carbone Cancer Center

Sections

NCCN Resources

Copyright © 2023 National Comprehensive Cancer Network, All Rights Reserved

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.